Sunflower Health updates on major asset restructuring plan

Zhejiang Sunflower Great Health Technology Co., Ltd. (the Company) announced progress on its major asset restructuring, which includes acquiring 100% equity in Zhangzhou Xipu Material Technology Co., Ltd. and 40% equity in Zhejiang Beide Pharmaceutical Co., Ltd., along with raising supporting funds. The transaction is classified as a connected transaction and a major asset restructuring.

The Company’s shares resumed trading on September 22, 2025, following a suspension initiated on September 8, 2025. This followed the disclosure of the "Preliminary Plan for Issuing Shares and Paying Cash to Acquire Assets and Raise Supporting Funds and Related Transactions" on September 22, 2025.

As of November 20, 2025, audit, valuation, and due diligence work for the transaction are progressing in an orderly manner. The Company will convene further board and shareholder meetings to approve the transaction upon completion of these processes. The transaction remains subject to approval by relevant regulatory bodies.